VEGFA and neoplasm: A single preclinical study demonstrated a direct effect of lurbinectedin on the tumour microenvironment, as it decreases the tumour-associated macrophages and circulating monocytes, and the angiogenic factor VEGF (vascular endothelial growth factor), with consequent reduced blood vessel density [50].